about
Respiratory viruses other than influenza virus: impact and therapeutic advancesSevere acute respiratory syndrome coronavirus as an agent of emerging and reemerging infectionA review of treatment modalities for Middle East Respiratory Syndrome.Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection.A severe acute respiratory syndrome-associated coronavirus-specific protein enhances virulence of an attenuated murine coronavirusChemical and biological mechanisms of pathogen reduction technologiesSevere acute respiratory syndrome (SARS): lessons learnt in Hong KongSevere acute respiratory syndrome coronavirus protein 6 mediates ubiquitin-dependent proteosomal degradation of N-Myc (and STAT) interactor.Role of interferons in the treatment of severe acute respiratory syndrome.Advancements in the battle against severe acute respiratory syndrome.Current status of anti-SARS agents.Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome.Treatment of severe acute respiratory syndrome.Potential antivirals and antiviral strategies against SARS coronavirus infections.Interference of ribosomal frameshifting by antisense peptide nucleic acids suppresses SARS coronavirus replication.A unique host defense pathway: TRIF mediates both antiviral and antibacterial immune responses.Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1.Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque.Inhibition of cytokine gene expression and induction of chemokine genes in non-lymphatic cells infected with SARS coronavirus.Characterization of the antiviral effects of interferon-alpha against a SARS-like coronoavirus infection in vitro.Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins.Clinical issues and research in respiratory failure from severe acute respiratory syndrome.Similarities of immune reactions between hepatitis C and severe acute respiratory syndrome-associated coronavirus infections.Severe acute respiratory syndromeWhite-nose syndrome is associated with increased replication of a naturally persisting coronaviruses in bats
P2860
Q24655957-8A730327-C7B8-49EB-B981-8FCB9C2F59C8Q28383088-B2840C16-648C-418B-A204-382BCB6E4F94Q30248209-54A8CFCD-519D-4F29-9D1A-F4046BC380B0Q30429521-E13A7217-E4A1-40EB-A451-FB98ACA9E9C0Q33525586-F023790D-05C3-40F4-8625-B7A7883D4A9DQ33930434-D37F4925-FC6E-4D4E-BC80-D1ECAF378048Q34777948-1D74FE5C-3BE9-4245-B419-48CDB9218A8DQ34974298-57EDDA1E-6B06-4F09-9415-BBBE69659D3BQ35613039-601EF57F-3B03-4387-98E9-F6486A07BA35Q35790834-FA2BFF06-297F-4BDF-BB3F-2310CF147715Q35841566-636B707F-AC51-4361-A5A0-96249100EF51Q36058652-11715BB0-0486-453A-BD85-79C1764C4437Q36140676-67ED0D0C-D536-429D-9A84-8809397DC586Q36261771-FBD944F4-FA63-4BB4-A0A4-89A7FF9621B7Q36441511-C2F60334-7E3C-4068-99E4-0C3501988A40Q36507714-9CE27D41-D5B4-419F-B0D9-2B841D298660Q36511199-0462F4F3-F26B-4BD6-96F5-D1ADF5E6C389Q37481314-79678233-513F-4094-AFC3-3768F0A70DC0Q37567955-004B7A80-0CE9-41BF-8B06-486F260086BBQ39362979-4DEEDE9D-2B75-45C0-8D4E-829CCFF858BCQ40298627-4DBB14AE-4484-46D1-94EF-B48F72FD6CC6Q40317281-2BE1B2BB-6728-49D6-AE69-9862C7BACCF7Q43280688-6D5F6EA0-B9F9-4CC4-A365-191C557E1F7BQ45011740-00DEFA01-5E52-47AB-9B15-694A89CDD06BQ45174339-39C11522-E94C-4220-B9F7-10B324F5CE35Q47724922-38D95E28-DAC1-4765-9B4F-F302EE626019Q56775278-D9D11C18-FCD6-4615-ADFA-BDE656E1E0A6Q57811550-B2068A97-EDAF-43D2-B6EB-B018218F9CD0
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Interferon-beta 1a and SARS coronavirus replication.
@en
Interferon-beta 1a and SARS coronavirus replication.
@nl
type
label
Interferon-beta 1a and SARS coronavirus replication.
@en
Interferon-beta 1a and SARS coronavirus replication.
@nl
prefLabel
Interferon-beta 1a and SARS coronavirus replication.
@en
Interferon-beta 1a and SARS coronavirus replication.
@nl
P2093
P2860
P50
P356
P1476
Interferon-beta 1a and SARS coronavirus replication.
@en
P2093
John W Huggins
Lisa E Fritz
Peter B Jahrling
P2860
P304
P356
10.3201/EID1002.030482
P577
2004-02-01T00:00:00Z